Videos

Susan M. O’Brien, MD, on the approved BTK inhibitors for treating chronic lymphocytic leukemia.

Sattva S. Neelapu, MD, spoke about continuing to look at results from the ZUMA-5 trial to determine if axicabtagene ciloleucel can cure patients with relapsed or refractory indolent non-Hodgkin lymphoma

Responses to questions by community hematologists/oncologists regarding optimal ways to diagnose and manage patients with myelofibrosis.

Clinical pearls for planning and sequencing therapy for patients with myelofibrosis.

Nina Shah, MD, discusses the biggest news from the FDA for multiple myeloma in the past year.

When asked about abstracts he thinks have the greatest potential to impact the standard of care in myeloma, Rafael Fonseca, MD, looked to emerging cellular therapies, specifically ciltacabtagene autoleucel for the treatment of heavily pretreated disease.

Susan M. O’Brien, MD, discussed the emergence of noncovalent BTK inhibitors for treating chronic lymphocytic leukemia.

Jennifer A. Woyach, MD, spoke about the results of a study conducted in elderly patients treated with an ibrutinib-containing regimen for chronic lymphocytic leukemia at 55 months of follow-up.

Reshma Mahtani, DO, discusses considerations for use of trastuzumab duocarmazine in HER2+ breast cancer.

Our panel of experts review the latest data on the antibody drug conjugate, trastuzumab duocarmazine.

Luciano Costa, MD, PhD, spoke about the primary end point analysis for the MASTER trial examining daratumumab, carfilzomib, lenalidomide, and dexamethasone in multiple myeloma.

Drs. Brown and Gupta discuss key takeaways from the study and the impact these data are likely to have on clinical practice.

Sattva S. Neelapu, MD, spoke about which abstracts he was most excited to see presented at the upcoming American Society of Hematology Annual Meeting.

Dr Choueiri presents the second patient case to the panel: a 53-year-old woman with renal cell carcinoma that underwent a nephrectomy.

Dr Orenstein details how he manages quality of life for patients with advanced renal cell carcinoma.

Aaron Berger, MD, shares unmet needs and challenges in managing patients with nmCRPC.

Dr Aaron Berger comments on quality of life data and the role of patient preference in nmCRPC.

A prostate cancer expert discusses comorbidities and dose alterations with next-generation androgen receptor inhibitors in nmCRPC.

Reshma Mahtani, DO, and Neil Iyengar, MD, discuss the data presented at ESMO 2021 in the TUXEDO-1 and HER2CLIMB-04 trials.

The panel analyzes the data from DESTINY-Breast03 and DESTINY-Breast01 and how these data will further impact practice.

Thomas G. Martin, MD, spoke about the updated results of the CARTITUDE-1 study examining ciltacabtagene autoleucel in relapsed or refractory multiple myeloma.

Sattva S. Neelapu, MD, spoke about the ZUMA-5 trial and the long-term follow-up results seen with axicabtagene ciloleucel in patients with relapsed or refractory indolent non-Hodgkin lymphoma.

Jennifer A. Woyach, MD, spoke about the phase 3 AO41202 study, which investigated different ibrutinib regimens for elderly patients with chronic lymphocytic leukemia.

Luciano Costa, MD, PhD, spoke about which abstracts he wants to see most at ASH 2021.

Thomas G. Martin, MD, spoke about the previously reported results of the CARTITUDE-1 study in patients with relapsed or refractory myeloma ahead of the 2021 ASH Annual Meeting.

Thomas G. Martin, MD, spoke about the abstracts regarding B-cell maturation antigen–targeted treatments he’s excited to see presented at ASH 2021.

Jennifer A. Woyach, MD, spoke about which abstracts she’s most excited to see presented at the 2021 American Society of Hematology Annual Meeting.

Shared insight on best practices in frontline maintenance therapy for metastatic urothelial carcinoma to improve patient outcomes.

Reviewing a patient case of metastatic urothelial carcinoma, experts discuss the selection of frontline and maintenance therapy.

Nina Shah, MD, touched on important abstracts being presented at the 2021 American Society of Hematology Annual Meeting.